Stock Groups

Vaccine Stocks Benefit From Covid-19 Variant Concerns -Breaking

[ad_1]


Sam Boughedda

Investing.com — After concerns about the existence of a coronavirus variant that could be transmitted to South Africa from Covid-19, vaccine stocks related to Covid-19 made gains on Friday.

Concerns have been raised over the possibility that this variant could evade vaccines. Stocks like Pfizer Inc (NYSE:), BioNTech SE (NASDAQ:), Moderna Inc (NASDAQ:), Inovio Pharmaceuticals Inc (NASDAQ:), Novavax Inc (NASDAQ:), Vir Biotechnology Inc (NASDAQ:), among others, have seen a surge. 

Pfizer shares rose 6%. Moderna rose 23%. Novavax shares increased by more than 9 percent, and Inovio shares rose over 8%. Vir gained 16%. The Vir lost more than 2 points (or 850) in the morning trading.

According to Reuters BioNTech claimed that they expect more data about the new variant within two weeks. It also stated that if needed, the company would be able redesign the vaccine within six weeks and to deliver batches in 100 days.

Some European countries are already seeing a reintroduction in lockdown restrictions. The cases have been increasing again. Additionally, some experts have called the variant “most alarming” but scientists continue to work to determine its consequences.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by market makers. As such, they may be incorrect and different from market prices. This means that prices cannot be used to trade. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]